Magnesium;diperchlorate

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 碱土金属氧阴离子化合物
• 英文名称: Magnesium;diperchlorate
• 化学式: Cl2MgO8
• 分子量: 223.2
• InChiKey: MPCRDALPQLDDFX-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -9.89
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  149
• 氢给体数：
  0
• 氢受体数：
  8

ADMET

代谢

没有证据表明高氯酸镁在体内被代谢。它通过泌尿系统迅速从体内排出（L894）。

There is no evidence that magnesium perchlorate is metabolized in the body. It is rapidly eliminated from the body through the urinary tract (L894).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 毒性总结

高氯酸根离子（高氯酸盐）的主要和最敏感的目标是甲状腺。高氯酸盐抑制血液中的碘化物（I-）进入甲状腺滤泡细胞。这种抑制作用被认为是通过高氯酸竞争性地阻止碘化物与一种载体，或钠/碘化物同向转运体（NIS）结合来实现的，该载体催化Na+和I-同时穿过甲状腺滤泡细胞的基底外侧膜。高氯酸盐对NIS的抑制可能会限制合成甲状腺激素甲状腺素（T4）和三碘甲状腺原氨酸（T3）所需的碘化物的可用性，进而可能影响循环中的T4和T3水平。所有已知的高氯酸盐对甲状腺激素系统的影响都直接或间接来源于对NIS的抑制。T3对于神经系统的正常发育和几乎所有身体组织的细胞代谢的调节至关重要。目标组织中T3的可用性中断可能导致对多种器官和系统产生不利影响（L894）。

The primary and most sensitive target of the perchlorate anion (perchlorate) is the thyroid gland. Perchlorate inhibits the transport of iodide (I-) from the blood into the thyroid follicle cells. The inhibition is thought to be accomplished by perchlorate competitively blocking iodide binding to a carrier, or sodium/iodide symporter (NIS), which catalyzes the simultaneous transfer of Na+ and I-across the basolateral membrane of thyroid follicle cells. Perchlorate inhibition of the NIS can limit the availability of iodide needed for the production of the thyroid hormones thyroxine (T4) and triiodothyronine (T3), which in turn, may affect the circulating levels of T4 and T3. All known effects of perchlorate on the thyroid hormone system derive directly or secondarily from the inhibition of the NIS. T3 is essential for normal development of the nervous system and for the regulation of metabolism of cells in nearly all tissues of the body. Disruption in the availability of T3 in target tissues can result in adverse effects on a wide variety of organs and systems (L894).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 致癌物分类

对人类不具有致癌性（未被国际癌症研究机构IARC列名）。

No indication of carcinogenicity to humans (not listed by IARC).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 健康影响

三碘甲状腺原氨酸（T3）对目标组织的可用性受到干扰，可能会对多种器官系统产生不利影响。受到T3水平干扰影响的器官系统包括皮肤、心血管系统、肺系统、肾脏、胃肠道、肝脏、血液、神经肌肉系统、中枢神经系统、骨骼、男性和女性生殖系统，以及包括垂体和肾上腺在内的许多内分泌器官。如此多的次要潜在目标突显了维持循环甲状腺激素充足水平的重要性。过氯酸盐是一种环境污染物，已知会通过阻止甲状腺中碘化物的积累来干扰下丘脑-垂体-甲状腺（HPT）轴。碘化物缺乏可能导致甲状腺功能减退和甲状腺肿大（L894, A267）。

Adverse effects on a wide variety of organ systems can result from disruption in the availability of T3 to target tissues. Organ systems affected by disturbances in T3 levels include the skin, cardiovascular system, pulmonary system, kidneys, gastrointestinal tract, liver, blood, neuromuscular system, central nervous system, skeleton, male and female reproductive systems, and numerous endocrine organs, including the pituitary and adrenal glands. Such an array of secondary potential targets underscores the need to maintain an adequate level of circulating thyroid hormones. Perchlorate, an environmental contaminant, is known to disturb the hypothalamus-pituitary-thyroid (HPT) axis by blocking iodide accumulation in the thyroid. Iodide deficiency can lead to hypothyroidism and goiter (L894, A267).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 暴露途径

吸入（L894）；口服（L894）；皮肤接触（L894）；眼睛接触（L894）。

Inhalation (L894) ; oral (L894) ; dermal (L894) ; eye contact (L894).

来源:Toxin and Toxin Target Database (T3DB)

毒理性

• 症状

对皮肤、眼睛和呼吸系统有刺激作用，具体取决于接触途径。接触后可能会出现食道或胃肠道刺激 (L894)。

Irritating to skin, eyes, and respiratory system, depending on the route of exposure. Esophageal or gastrointestinal tract irritation could occur following exposures (L894).

来源:Toxin and Toxin Target Database (T3DB)

反应信息

• 作为反应物：
  描述：

  (R)-4-(2-Oxo-2-phenyl-ethyl)-1-propyl-1,4-dihydro-pyridine-3-carboxylic acid phenylamide 、 Magnesium;diperchlorate 以67%的产率得到
  参考文献：
  名称：

  MASHRAQUI, S. H.;KELLOGG, R. M., J. AMER. CHEM. SOC., 1983, 105, N 26, 7792-7793

  摘要：

  DOI：
• 作为产物：
  描述：

  氯化镁 生成 Magnesium;diperchlorate
  参考文献：
  名称：

  PUSHPAVANAM, S.;MOHAN, S.;VASUDEVAN, S.;RAVICHANDRAN, S. NARASIMHAM K. C., BULL. ELECTROCHEM., 6,(1990) N, C. 422-423

  摘要：

  DOI：
• 作为试剂：
  描述：

  4-甲氧基苯甲醛 、 环丁基胺 、 Sodium sulfate-III 、 硼氢化钠 在 Magnesium;diperchlorate 甲醇 、 乙酸乙酯 、 Sodium sulfate-III 作用下， 以 二氯甲烷 、 sodium hydroxide 为溶剂， 反应 21.0h， 以to isolate 4A (8.5 g, 82% yield) as a clear oil的产率得到N-(4-甲氧苄基)环丁胺
  参考文献：
  名称：

  IMIDAZOPYRIDAZINECARBONITRILES USEFUL AS KINASE INHIBITORS

  摘要：

  该发明提供了式(I)的化合物及其药学上可接受的盐。式(I)的咪唑吡啶酮类化合物抑制蛋白激酶活性，因此可用作抗癌剂。

  公开号：

  US20100113458A1

文献信息

• 4-substituted benzopyran and related compounds
  申请人：Brisol-Myers Squibb Company

  公开号：US05393771A1

  公开（公告）日：1995-02-28

  Compounds having the formula ##STR1## and pharmaceutically acceptable salts thereof. These compounds have potassium channel activating activity and are useful, therefore for example, as cardiovascular agents.

  具有公式##STR1##及其药学上可接受的盐的化合物。这些化合物具有钾通道激活活性，因此例如作为心血管药物是有用的。
• Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps)
  申请人：Swinnen Dominique

  公开号：US20050124656A1

  公开（公告）日：2005-06-09

  The present invention is related to substituted methylene amide derivatives of formula (I) and use thereof for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or pyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of substituted methylene amide derivatives of formula (I) to modulate, notably to inhibit the activity of PTPs. Also the present invention relates to a method of treating diabetes type II, obesity and to regulate the appetite of mammals. The present invention is furthermore related to novel substituted methylene amide derivatives and method of preparation thereof. Formula (I).

  本发明涉及公式（I）的取代亚甲基酰胺衍生物及其用于治疗和/或预防由胰岛素抵抗或高血糖引起的代谢障碍，包括1型和/或2型糖尿病、不足的葡萄糖耐受性、胰岛素抵抗、高脂血症、高三酰甘油血症、高胆固醇血症、肥胖症、多囊卵巢综合症（PCOS）。特别是，本发明涉及使用公式（I）的取代亚甲基酰胺衍生物来调节，尤其是抑制PTP的活性。本发明还涉及一种治疗2型糖尿病、肥胖症和调节哺乳动物食欲的方法。此外，本发明还涉及新的取代亚甲基酰胺衍生物及其制备方法。公式（I）。
• Phosphorus containing compounds as antihypercholesterolemic and
  申请人：Warner-Lambert Company

  公开号：US05208224A1

  公开（公告）日：1993-05-04

  Novel phosphorus containing compounds are described, as well as methods for the preparation and pharmaceutical composition of same, which are useful in preventing the intestinal absorption of cholesterol and thus are useful in the treatment of hypercholesterolemia and atherosclerosis.

  本发明描述了一种新型含磷化合物，以及制备方法和制备相同的药物组合物，其有助于防止胆固醇的肠道吸收，因此对于高胆固醇血症和动脉粥样硬化的治疗有用。
• Hypotensive piperidine derivatives
  申请人：——

  公开号：US04446141A1

  公开（公告）日：1984-05-01

  The present invention relates to a novel compound represented by the general formula: ##STR1## wherein Ar represents a naphthyl, phenyl or substituted phenyl group, Q represents ##STR2## wherein R.sub.1 represents a hydrogen atom, or an alkyl, alkanoyl or alkoxycarbonyl group, R represents a hydrogen atom or an alkyl group, and Z represents a substituted benzimidazolinyl group; the broken line in piperidine ring means that 3,4-positions in the piperidine ring are saturated or form a double bond. Said compound and the pharmaceutically acceptable acid addition salts thereof have a hypotensive action and therefore are useful as medicine.

  本发明涉及一种新型化合物，其通式为：##STR1## 其中，Ar代表萘基、苯基或取代苯基，Q代表##STR2## 其中，R.sub.1代表氢原子，或烷基、烷酰基或烷氧羰基基团，R代表氢原子或烷基，Z代表取代苯并咪唑啉基团；哌啶环中的虚线表示哌啶环的3,4位饱和或形成双键。该化合物及其药学上可接受的酸盐具有降压作用，因此可用作药物。
• Dihetero-substituted metalloprotease inhibitors
  申请人：The Procter & Gamble Company

  公开号：US20030225074A1

  公开（公告）日：2003-12-04

  Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): 1 where J, M, Q, T, W, X, Z, R 1 , R 2 , R 3 , R 4 , R 4′ , R 5 , R 6 , R 6′ , R 7 , m, and n have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also disclosed are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

  本发明涉及一种金属蛋白酶抑制剂化合物，用于治疗由这些酶的过度活性引起的疾病。特别地，该化合物具有以下式(I)的结构：其中J、M、Q、T、W、X、Z、R1、R2、R3、R4、R4'、R5、R6、R6'、R7、m和n在规范中有所描述。本发明还包括该式的光学异构体、对映异构体和对映体，以及其药物可接受的盐、生物可水解的酰胺、酯和亚酰酰胺。还公开了包含这些化合物的药物组合物，以及使用该化合物或药物组合物治疗或预防金属蛋白酶相关疾病的方法。

表征谱图